Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mizagliflozin in post-bariatric hypoglycemia
NCT05721729Phase 2Completed
- Sponsor
- Vogenx
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mizagliflozin in post-bariatric hypoglycemia (PBH), sponsored by Vogenx. Started Jun 2023; status: completed.
02
Drugs
mizagliflozin
03
Conditions
post-bariatric hypoglycemia (PBH)
Beyond the preview
Go deeper on NCT05721729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05721729.